CEL-SCI (NYSE:CVM) Announces Earnings Results

CEL-SCI (NYSE:CVMGet Free Report) announced its quarterly earnings results on Thursday. The company reported ($0.14) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.14), reports.

CEL-SCI Price Performance

CEL-SCI stock opened at $1.27 on Friday. CEL-SCI has a fifty-two week low of $1.04 and a fifty-two week high of $3.23. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.67 and a quick ratio of 0.78. The stock has a 50-day simple moving average of $1.68 and a 200-day simple moving average of $2.21.

Insider Activity

In other news, Director Robert Eugene Watson bought 20,000 shares of CEL-SCI stock in a transaction dated Wednesday, May 8th. The stock was acquired at an average cost of $1.39 per share, with a total value of $27,800.00. Following the acquisition, the director now owns 24,431 shares of the company’s stock, valued at $33,959.09. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, CEO Geert R. Kersten acquired 30,000 shares of CEL-SCI stock in a transaction on Wednesday, May 8th. The stock was purchased at an average cost of $1.39 per share, with a total value of $41,700.00. Following the purchase, the chief executive officer now directly owns 1,195,309 shares in the company, valued at $1,661,479.51. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Robert Eugene Watson acquired 20,000 shares of CEL-SCI stock in a transaction on Wednesday, May 8th. The shares were bought at an average cost of $1.39 per share, with a total value of $27,800.00. Following the completion of the purchase, the director now owns 24,431 shares in the company, valued at $33,959.09. The disclosure for this purchase can be found here. In the last three months, insiders bought 58,000 shares of company stock valued at $80,620. Insiders own 16.24% of the company’s stock.

Institutional Trading of CEL-SCI

Several institutional investors and hedge funds have recently added to or reduced their stakes in CVM. Tidal Investments LLC purchased a new stake in CEL-SCI during the 1st quarter valued at approximately $27,000. Chilton Capital Management LLC raised its stake in CEL-SCI by 297.4% during the 1st quarter. Chilton Capital Management LLC now owns 16,302 shares of the company’s stock valued at $31,000 after acquiring an additional 12,200 shares during the last quarter. Tower Research Capital LLC TRC raised its stake in CEL-SCI by 2,011.9% during the 4th quarter. Tower Research Capital LLC TRC now owns 16,198 shares of the company’s stock valued at $44,000 after acquiring an additional 15,431 shares during the last quarter. Forthright Family Wealth Advisory LLC purchased a new stake in CEL-SCI during the 4th quarter valued at approximately $45,000. Finally, Sheets Smith Wealth Management acquired a new position in CEL-SCI during the 4th quarter worth approximately $54,000. 12.08% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, StockNews.com downgraded CEL-SCI from a “hold” rating to a “sell” rating in a report on Friday, March 15th.

Read Our Latest Report on CVM

About CEL-SCI

(Get Free Report)

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.

Further Reading

Earnings History for CEL-SCI (NYSE:CVM)

Receive News & Ratings for CEL-SCI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CEL-SCI and related companies with MarketBeat.com's FREE daily email newsletter.